Cardiovascular diseases claim over 10 million lives annually, highlighting the critical need for long-term monitoring and early detection of cardiac abnormalities. Existing techniques like electrocardiograms (ECG) and Holter are accurate but suffer from discomfort caused by body-attached electrodes. While wearable devices using photoplethysmography offer more convenience, they sacrifice accuracy and are susceptible to environmental interference. Here we present a radio frequency (RF)-based (60 to 64 GHz) sensing system that monitors long-term heart rate variability (HRV) with clinical-grade accuracy. Our system successfully overcomes the orders-larger interference from respiration motion in far-field conditions without any model training. By identifying previously undiscovered frequency ranges (beyond 10-order heartbeat harmonics) where heartbeat information predominates over other motions, we generate prominent heartbeat patterns with harmonics typically considered detrimental. Extensive evaluations, including a large-scale outpatient setting involving 6,222 eligible participants and a long-term daily life scenario, where sleep data was collected over 5 separate random nights over two months and a continuous 21-night period, demonstrate that our system can monitor HRV and identify abnormalities with comparable performance to clinical-grade ECG-based systems. This RF-based HRV sensing system has the potential to support active self-assessment and revolutionize medical prevention with long-term and precise health monitoring.

Rationale: The transition from acute inflammation to fibrosis following myocardial ischemia‒reperfusion (MIR) significantly affects prognosis. Macrophages play a pivotal role in inflammatory damage and repair after MIR. However, the heterogeneity and transformation mechanisms of macrophages during this transition are not well understood.

Background: The clinical benefits of omega-3 fatty acids (FAs) supplementation in preventing and treating coronary heart disease (CHD) remain controversial. Therefore, this study aimed to investigate the clinical benefits of omega-3 FA supplementation, with special attention given to specific subgroups.Methods: Randomized controlled trials (RCTs) that compared the effects of omega-3 FA supplementation for CHD vs. a control group and including at least 1,000 patients were eligible for the inclusion in this meta-analysis. The relative risk (RR) of all-cause death, major adverse cardiovascular events (MACEs), cardiovascular death, myocardial infarction (MI), stroke, and revascularization were estimated. We analyzed the association between cardiovascular risk and omega-3 FA supplementation in the total subjects. We focused on the cardiovascular risk compared to omega-3 FA in subgroups with different development stages of CHD, omega-3 FA supplementation application dose, diabetes, and sex. PROSPERO Registration Number: CRD42021282459.Results: This meta-analysis included 14 clinical RCTs, including 1,35,291 subjects. Omega-3 FA supplementation reduced the risk of MACE (RR; 0.95; CI: 0.91–0.99; p for heterogeneity 0.27; I² = 20%; p = 0.03), cardiovascular death (RR; 0.94; CI: 0.89–0.99; p for heterogeneity 0.21; I² = 25%; p = 0.02), and MI (RR; 0.86; CI: 0.79–0.93; p for heterogeneity 0.28; I² = 19%; p < 0.01), but had no significant effect on all-cause death, stroke, and revascularization. In the subgroup analysis, omega-3 FA supplementation decreased the incidence of MACE and cardiovascular death in acute patients with MI, the risk of MI and stroke in patients with CHD, and the risk of MI in patients with high-risk CHD. 0.8–1.2 g omega-3 FA supplementation reduced the risk of MACE, cardiovascular death, and MI. It was revealed that gender and diabetes have no significant association between omega-3 FA supplementation and MACE risk.Conclusions: Omega-3 FA supplementation had a positive effect in reducing the incidence of MACE, cardiovascular death, MI. Regardless of the stage of CHD, omega-3 FA supplementation can prevent the occurrence of MI. The 0.8–1.2 g omega-3 FA supplementation alleviated CHD risk more effectively than lower or higher doses.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42021282459.

Role of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling - Article abstract #934255